Save the date for this ILD Conference in 2014
We are pleased to announce the conference "Fibrosing interstitial lung
diseases of idiopathic and exogenous origin -Phenotype approach" which
will be held in the beautiful city of Prague (Czech Republique), June
19-21, 2014. View our flyer
WASOG 2013 Conference
We are pleased to invite you to participate in the 6th International
WASOG Conference on Diffuse Parenchymal Lung Diseases, Paris, June 6-7,
2013. The conference will focus on idiopathic pulmonary fibrosis,
sarcoidosis and other interstitial lung diseases. The conference will be
held in La Sorbonne, one of the most prestigious centers of intelligence
and culture, of science and of the arts in France. For more information
visit the conference website:
- Registration fee increases from April 1st, 2013!
- Deadline for registration: June 5th, 2013.
- Abstract submission deadline EXTENDED
again: April 15th 2013!!
Follow WASOG on LinkedIn, Twitter and via our e-Newsletter
In addition to this website WASOG will keep you informed using
several media. Updates include WASOG news, conference updates and other
relevant information we would like to share with you. We therefore
invitite you to subscribe to our e-Newsletter
and/or follow @wasog on Twitter
You may also join our group on
to expand your professional network and participate in discussions.
Sarcoidosis and other ild around the world
To inform you about sarcoidosis and other ild in different countries we ask(ed)
colleagues to summarize the prevalence, the research and important websites, etc. This topic has been added to the WASOG site.
WASOGBAL 2014 Announced!
The 3rd joint WASOGBAL conference (10th WASOG Meeting and the 12th
International Conference on BAL) will be held in Izmir, Turky, October
View our flyer
Any news will be posted here on the website and communicated through the
e-newsletter and twitter.
Efficacy and safety of implantable cardiac defibrillators for
treatment of ventricular arrhythmias in patients with cardiac
sarcoidosis, by Kron et al. Implantable cardiac defibrillator (ICD)
implantation is a class IIA recommendation for patients with cardiac
sarcoidosis (CS). However, little is known about the efficacy and safety
of ICDs in this population. A multicentre retrospective data review
evaluated the efficacy and safety of ICDs in patients with CS. Data were
collected on 235 patients from 13 institutions, 64.7% male with mean age
55.6 ± 11.1. Over a mean follow-up of 4.2 ± 4.0 years, 85 of 234 (36.2%)
patients received an appropriate ICD therapy (shocks and/or
anti-tachycardia pacing) and 67 of 226 (29.7%) received an appropriate
shock. Patients with CS and ICDs are at high risk for ventricular
arrhythmias. This population also has high rates of inappropriate shocks
and device complications.
Global burden of chronic pulmonary aspergillosis complicating
sarcoidosis, by Denning et al. Chronic pulmonary aspergillosis (CPA)
may complicate pulmonary sarcoidosis. The global burden of sarcoidosis
and the burden of CPA complicating sarcoidosis was re-estimated. We
searched the literature and reference lists of retrieved papers to
identify all published sarcoidosis incidence and prevalence data. We
estimated the frequency of CPA from 11 papers relating to >3,000
patients with sarcoidosis to derive CPA patient numbers. We applied an
annual attrition rate of 15% (range 10–25%) to estimate the global
burden of CPA. As CPA responds to long-term antifungal therapy, which
may prevent life-threatening haemoptysis, screening periodically for CPA
in those with pulmonary sarcoidosis may be important, especially in
patients requiring corticosteroid therapy.
Severity of pulmonary involvement and (18)F-FDG PET activity in
sarcoidosis, by Mostard RL, et al. Assessing inflammatory activity
is useful in the management of persistent symptomatic sarcoidosis
patients. (18)F-FDG PET (PET) has been shown to be a sensitive technique
to assess inflammatory activity in sarcoidosis. The aim of this study
was to evaluate whether the severity of pulmonary involvement is
associated with PET activity in persistent symptomatic sarcoidosis
patients (n=95). The severity of the pulmonary involvement, assessed by
HRCT features and lung function parameters, appeared to be associated
with PET activity in sarcoidosis. The majority of patients with fibrotic
changes demonstrated inflammatory activity at pulmonary and
Safety and efficacy of ARA290 in sarcoidosis patients with symptoms
of small fiber neuropathy: a randomized, double blind, pilot study
by Heij et al. ARA290, a peptide designed to activate the innate repair
receptor that arrests injury and initiates cytoprotection,
anti‐inflammation, and healing, reduces allodynia in preclinical
neuropathy models. We studied the safety and efficacy of ARA 290 to
reduce symptoms of small fiber neuropathy (SFN) in 22 patients with
sarcoidosis. ARA 290 appears to be safe in patients with sarcoidosis and
to reduce neuropathic symptoms.
Find all our selected literure on our